AXSOME THERAPEUTICS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
AXSOME THERAPEUTICS, INC. (AXSM) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $314.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2023-05-09
- AXSOME THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-03-31 was $314.00K, a 14.18% increase year-over-year.
- AXSOME THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-12-31 was $324.53K, a 17.43% increase year-over-year.
- AXSOME THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-09-30 was $283.01K, a 3.85% increase year-over-year.
- AXSOME THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-06-30 was $278.96K, a 4.22% increase year-over-year.
- AXSOME THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $1.16M, a 7.62% increase from fiscal 2021.
- AXSOME THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $1.08M, a 1904.15% increase from fiscal 2020.
- AXSOME THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2020 was $53.85K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month as first filed | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|---|
| 2023-03-31 | $314.00K 10-Q · filed 2023-05-09 | $638.53K derived: sum of 2 quarters · filed 2023-05-09 | $921.54K derived: sum of 3 quarters · filed 2023-05-09 | $1.20M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2022-12-31 | $324.53K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $607.54K derived: sum of 2 quarters · filed 2023-02-28 | $886.50K derived: sum of 3 quarters · filed 2023-02-28 | $1.16M 10-K · filed 2023-02-28 | |
| 2022-09-30 | $283.01K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $561.97K derived: sum of 2 quarters · filed 2022-11-07 | $836.97K 10-Q · filed 2022-11-07 | $1.11M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2022-06-30 | $278.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $553.96K 10-Q · filed 2022-08-09 | $830.32K derived: sum of 3 quarters · filed 2023-05-09 | $1.10M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2022-03-31 | $275.00K 10-Q · filed 2023-05-09 | $275.06K 10-Q · filed 2022-05-02 | $551.36K derived: sum of 2 quarters · filed 2023-05-09 | $823.88K derived: sum of 3 quarters · filed 2023-05-09 | $1.09M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $276.36K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $548.88K derived: sum of 2 quarters · filed 2023-02-28 | $816.55K derived: sum of 3 quarters · filed 2023-02-28 | $1.08M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $272.51K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $540.18K derived: sum of 2 quarters · filed 2022-11-07 | $802.95K 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | $267.67K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $530.44K 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | $262.76K 10-Q · filed 2022-05-02 | ||||
| 2020-12-31 | $53.85K 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |